FIELD: biotechnology.
SUBSTANCE: what is described is a recombinant viral vector for treating and preventing cancer. Specifically described is a recombinant oncolytic virus containing one or more copies of two or more target sequences of tumor-suppressing micro-RNA (miR), inserted into two or more loci of viral genes required for viral replication, wherein the recombinant oncolytic virus is a herpes simplex virus (HSV), wherein two or more loci of viral genes required for viral replication contain an ICP4 locus, and the ICP4 locus comprises at least one copy of the target sequence of miR-124.
EFFECT: invention widens range of agents for treating cancer.
88 cl, 49 dwg, 8 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
ONCOLYTIC VIRAL VECTORS AND THEIR APPLICATION | 2018 |
|
RU2771110C2 |
MARKERS OF TUMOR CELL RESPONSE TO ANTI-CANCER THERAPY | 2014 |
|
RU2664180C2 |
METHOD FOR BREAST CANCER SCREENING AND PREDISPOSITION TO IT | 2019 |
|
RU2705344C1 |
QUINOLINE DERIVATIVES FOR USE IN TREATMENT OR PREVENTION OF CANCER | 2019 |
|
RU2811417C2 |
ANALYTICAL SYSTEM FOR DIAGNOSING LUNG CANCER USING FREE AND CIRCULATING MICRO-RNAS ASSOCIATED WITH BLOOD CELLS | 2020 |
|
RU2755651C1 |
METHOD FOR DIAGNOSTICS AND TREATMENT OF OBLIGATE PRECANCER DISEASES AND CA IN SITU | 2021 |
|
RU2794856C2 |
METHODS FOR PATHOLOGICAL CHANGES DETECTION IN ORGAN OR SYSTEM OF ORGANS | 2012 |
|
RU2626540C2 |
METHOD FOR ASSESSING RESISTANCE OF SQUAMOUS CELL CANCER OF THROAT TO RADIATION THERAPY AND SET OF TESTS FOR IMPLEMENTATION THEREOF | 2022 |
|
RU2818356C1 |
COMBINATIONS | 2015 |
|
RU2715236C2 |
METHODS OF TREATING CANCER DISEASES AND TUMORS USING PDE1 INHIBITORS | 2019 |
|
RU2811918C2 |
Authors
Dates
2021-06-03—Published
2017-01-27—Filed